E79.0

Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Hyperuricemia is defined as a serum urate concentration exceeding the solubility limit of monosodium urate in extracellular fluids, typically measured as >6.8 mg/dL or >7.0 mg/dL depending on laboratory standards. Code E79.0 specifically identifies patients with elevated serum uric acid who do not currently manifest clinical symptoms of gout, such as acute inflammatory arthritis, chronic tophaceous deposits, or uric acid-related nephrolithiasis. While the condition itself is often an incidental laboratory finding, chronic asymptomatic hyperuricemia is strongly associated with cardiovascular risk, hypertension, chronic kidney disease, and metabolic syndrome. The physiological threshold for crystal formation is approximately 6.8 mg/dL at normal body temperature, and levels exceeding this increase the risk of subclinical crystal deposition in joints and tendons, which may eventually progress to clinical gout.

Clinical Symptoms

  • Asymptomatic (by definition)
  • Elevated serum uric acid (>7.0 mg/dL in men, >6.0 mg/dL in women)
  • Incidental laboratory finding
  • Absence of joint pain or swelling
  • Absence of visible or palpable tophi
  • Subclinical urate crystal deposition (detectable only by DECT or ultrasound)
  • Co-occurrence with hypertension
  • Co-occurrence with metabolic syndrome markers

Common Causes

  • Renal underexcretion of uric acid (most common mechanism)
  • Dietary purine overload (excessive consumption of red meat, organ meats, or seafood)
  • Excessive alcohol consumption (particularly beer and spirits)
  • High fructose corn syrup consumption
  • Obesity and insulin resistance
  • Use of thiazide or loop diuretics
  • Low-dose aspirin therapy
  • Chronic kidney disease (reduced glomerular filtration)
  • Overproduction due to rapid cell turnover (e.g., psoriasis, hemolytic anemia)
  • Genetic variants in urate transporters (e.g., SLC2A9, ABCG2)

Documentation & Coding Tips

Explicitly confirm the absence of clinical gout symptoms to support the use of E79.0 over M10 series codes.

Example: Patient presents for follow-up of metabolic syndrome. Serum uric acid is elevated at 8.9 mg/dL. Physical examination of bilateral first metatarsophalangeal joints, ankles, and knees reveals no erythema, warmth, or swelling. No subcutaneous tophi noted on olecranon or pinnae. Patient denies history of acute joint pain episodes. Asymptomatic hyperuricemia (E79.0) is diagnosed, likely secondary to chronic HCTZ use for hypertension (I10). Plan: Monitor renal function and dietary counseling.

Billing Focus: Documentation must specify the absence of localized joint inflammation and tophaceous deposits to distinguish from more complex gout codes.

Document the underlying etiology or contributing medications when hyperuricemia is secondary.

Example: Hyperuricemia (E79.0) noted in the setting of Stage 3b Chronic Kidney Disease (N18.32). Patient also takes Furosemide 40mg daily for Congestive Heart Failure (I50.9). Uric acid 9.2 mg/dL. No evidence of urate crystal deposition disease or inflammatory arthritis upon exam of multiple joints.

Billing Focus: Identify drug-induced factors or renal impairment as these may require secondary ICD-10 codes like Z79.1 (Long term use of NSAIDs) or specific T-codes for adverse effects.

Specify the laboratory values and the patient's adherence to dietary modifications.

Example: Asymptomatic hyperuricemia (E79.0) persists despite low-purine diet. Current serum urate 8.4 mg/dL (Baseline 9.5). Patient remains asymptomatic with no clinical signs of inflammatory arthritis. Will continue observation without pharmacologic urate-lowering therapy at this time.

Billing Focus: Quantifiable lab data supports the medical necessity of the evaluation and management level chosen.

Differentiate between idiopathic hyperuricemia and metabolic syndrome components.

Example: 64-year-old male with Metabolic Syndrome (E88.81), Type 2 Diabetes (E11.9), and asymptomatic hyperuricemia (E79.0). Uric acid 8.1 mg/dL. No history of podagra or nephrolithiasis. Current BMI 34.2 (E66.9). Documentation reflects hyperuricemia as part of the cluster of metabolic disturbances.

Billing Focus: Ensures all components of metabolic syndrome are captured individually if not fully encapsulated by a single code.

Note the absence of renal calculi if imaging was performed for related concerns.

Example: CT Abdomen/Pelvis performed for vague flank pain showed no evidence of urolithiasis (N20.0). However, labs incidentally show uric acid 10.1 mg/dL. Physical exam negative for tophi or synovitis. Diagnosis: Hyperuricemia without signs of inflammatory arthritis (E79.0).

Billing Focus: The negative imaging finding justifies the use of E79.0 rather than N20.0 or M10.x codes.

Relevant CPT Codes

Related Diagnoses

Hierarchy